Stereotactic Ablative Radiotherapy (SABR) is an effective non-surgical alternative treatment for early stage, inoperable, Non Small Cell Lung Cancer (SABR UK Consortium, 2016). These patients are often elderly with co-morbidities. Treatments can be delivered in 3, 5 or 8 sessions (‘fractions’); often decided based on the proximity of the normal tissues to the tumour, with treatments close to the chest wall frequently delivered in 5-8 fractions. This means extra hospital trips for the patient and additional radiotherapy resource. The primary aim of this research is to determine if the calculation of the radiobiological dose to the chest wall and ribs can easily be used to personalise the number of treatment fractions.
Are women invisible in SABR research? Proffered paper at UK SABR Conference 2019